AU2024314540A1 - Crystal of nitrogen-containing heterocyclic compound having nrf2 activation effect - Google Patents
Crystal of nitrogen-containing heterocyclic compound having nrf2 activation effectInfo
- Publication number
- AU2024314540A1 AU2024314540A1 AU2024314540A AU2024314540A AU2024314540A1 AU 2024314540 A1 AU2024314540 A1 AU 2024314540A1 AU 2024314540 A AU2024314540 A AU 2024314540A AU 2024314540 A AU2024314540 A AU 2024314540A AU 2024314540 A1 AU2024314540 A1 AU 2024314540A1
- Authority
- AU
- Australia
- Prior art keywords
- crystal
- compound
- powder
- diffraction
- diffraction angles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023100075 | 2023-06-19 | ||
| JP2023-100075 | 2023-06-19 | ||
| PCT/JP2024/022040 WO2024262491A1 (ja) | 2023-06-19 | 2024-06-18 | Nrf2活性化作用を有する含窒素複素環化合物の結晶 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2024314540A1 true AU2024314540A1 (en) | 2025-11-27 |
Family
ID=93935419
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2024314540A Pending AU2024314540A1 (en) | 2023-06-19 | 2024-06-18 | Crystal of nitrogen-containing heterocyclic compound having nrf2 activation effect |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP4696692A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7904995B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20260023529A (cg-RX-API-DMAC7.html) |
| CN (1) | CN121152792A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2024314540A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL324833A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2025014082A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202504613A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2024262491A1 (cg-RX-API-DMAC7.html) |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6326507B1 (en) | 1998-06-19 | 2001-12-04 | Trustees Of Dartmouth College | Therapeutic compounds and methods of use |
| TWI649330B (zh) | 2013-04-24 | 2019-02-01 | 艾伯維有限公司 | 甲基巴多索龍之2,2-二氟丙醯胺衍生物、其多晶形及其使用方法 |
| US20190380992A1 (en) | 2014-12-04 | 2019-12-19 | Biogen Ma Inc. | Multiple Sclerosis Treatment Regimen Using Dimethyl Fumarate |
| JP2020097526A (ja) * | 2017-03-28 | 2020-06-25 | 武田薬品工業株式会社 | 複素環化合物 |
| JOP20210030A1 (ar) | 2018-08-20 | 2021-02-16 | Janssen Pharmaceutica Nv | مثبطات تفاعل البروتين-بروتين KEAP1-Nrf2 |
| KR102932313B1 (ko) | 2019-02-15 | 2026-02-26 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | Nrf2 활성화제로서 히드록시피리드옥사제핀 |
| CN114174289B (zh) | 2019-05-31 | 2025-03-07 | Ube株式会社 | 苯并三唑衍生物 |
| GB202005852D0 (en) | 2020-04-22 | 2020-06-03 | C4X Discovery Ltd | Therapeutic compounds |
| CN114507181B (zh) | 2020-11-17 | 2024-03-26 | 中国医学科学院药物研究所 | 含5-取代四氢异喹啉的丙酸类化合物、其药物组合物和应用 |
| CR20240325A (es) | 2022-01-07 | 2024-11-22 | Chugai Pharmaceutical Co Ltd | Compuesto heterocíclico que contiene nitrógeno que tiene un efecto de activación del nrf2 |
-
2024
- 2024-06-18 EP EP24825892.3A patent/EP4696692A1/en active Pending
- 2024-06-18 AU AU2024314540A patent/AU2024314540A1/en active Pending
- 2024-06-18 TW TW113122470A patent/TW202504613A/zh unknown
- 2024-06-18 KR KR1020257042624A patent/KR20260023529A/ko active Pending
- 2024-06-18 CN CN202480033461.0A patent/CN121152792A/zh active Pending
- 2024-06-18 IL IL324833A patent/IL324833A/en unknown
- 2024-06-18 WO PCT/JP2024/022040 patent/WO2024262491A1/ja not_active Ceased
- 2024-06-18 JP JP2025528066A patent/JP7904995B2/ja active Active
-
2025
- 2025-11-25 MX MX2025014082A patent/MX2025014082A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202504613A (zh) | 2025-02-01 |
| JP7904995B2 (ja) | 2026-08-13 |
| IL324833A (en) | 2026-01-01 |
| MX2025014082A (es) | 2026-01-07 |
| KR20260023529A (ko) | 2026-02-20 |
| EP4696692A1 (en) | 2026-02-18 |
| JPWO2024262491A1 (cg-RX-API-DMAC7.html) | 2024-12-26 |
| CN121152792A (zh) | 2025-12-16 |
| WO2024262491A1 (ja) | 2024-12-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103694236B (zh) | 一种嘧啶骨架具有刺猬通路拮抗剂活性的抗肿瘤化合物 | |
| CN109776445B (zh) | 苯并噁二唑类化合物及其制备方法和医药用途 | |
| CN110582491B (zh) | Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途 | |
| WO2023011513A1 (zh) | Shp2抑制剂、包含其的药物组合物及其用途 | |
| CN114685488A (zh) | 作为sos1抑制剂的化合物及其应用 | |
| JP7017801B2 (ja) | Creb結合タンパク質(cbp)の阻害 | |
| WO2015127872A1 (zh) | 2,4-二取代苯-1,5-二胺衍生物及其应用以及由其制备的药物组合物和药用组合物 | |
| CN115867556A (zh) | Lpa受体拮抗剂及其用途 | |
| JP7286299B2 (ja) | 1-メチル-d-トリプトファンの塩及びプロドラッグ | |
| EP3789383B9 (en) | Inhibitors of the trpc3 or trpc6 channel | |
| JP7835446B2 (ja) | 新規な複素環式化合物 | |
| EP3209652B1 (en) | Tricyclic atropisomer compounds | |
| CN110198938A (zh) | 作为蛋白质聚集调节剂的双-杂芳基衍生物 | |
| JP2024505732A (ja) | ピリドピリミジノン系誘導体及びその製造方法と使用 | |
| CN108727295A (zh) | 一种2-(3-氨基苯基)-苯并噻唑衍生物及其制备方法和用途 | |
| CN111377873A (zh) | 氨基嘧啶化合物及其制备方法和用途 | |
| CN102757448B (zh) | 大环类激酶抑制剂化合物、制备方法及其作为药物的应用 | |
| CN113272315B (zh) | 一类类固醇化合物及其用途 | |
| CA3291766A1 (en) | Crystal of nitrogen-containing heterocyclic compound having nrf2 activation effect | |
| IL324833A (en) | Crystal of a nitrogen-containing heterocyclic compound with an Nrf2 activating effect | |
| WO2019166616A1 (en) | Pyrazole derivatives as nhibitors of the wnt signalling pathway | |
| CN116640122A (zh) | Ikzf2降解剂及包含其的药物组合物和用途 | |
| WO2019141096A1 (zh) | 取代脲类化合物及其制备方法和用途 | |
| WO2026042088A1 (en) | Trycyclic derivatives and their use as complement factor b inhibitors | |
| WO2026092276A1 (zh) | 用于抑制ptpn蛋白的化合物及其用途 |